Barclays Downgrades Enanta Pharmaceuticals (ENTA) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
JMP Securities Upgrades Enanta Pharmaceuticals (ENTA) to Market Outperform
October 23, 2015 7:01 AM EDTJMP Securities upgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Market Perform to Market Outperform with a price target of $32.00.
For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.
Shares of Enanta Pharmaceuticals closed at $23.90 yesterday.
... MoreEnanta Pharma (ENTA) Halted on Second LUDP
October 22, 2015 3:30 PM EDTEnanta Pharma (NASDAQ: ENTA) Halted on Second LUDP
... MoreEnanta Pharma (ENTA) Drops Over 50%
October 22, 2015 3:29 PM EDTEnanta Pharma (NASDAQ: ENTA) shares dropped over 50% after the FDA warned of serious liver injury risk with Viekira Pak.
... MoreEnanta Pharma (ENTA) triggers limit-up, limit-down trading pause
October 22, 2015 3:14 PM EDTEnanta Pharma (NASDAQ: ENTA) triggers limit-up, limit-down trading pause. The activity is related to Abbvie news.
... More